Connect with us
nairametrics

Coronavirus

UK to roll out COVID-19 vaccine in less than 3 months and mass vaccination by Easter

British scientists have indicated a mass roll-out of COVID-19 vaccines in a few months time.

Published

on

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns, COVID-19: J&J starts vaccine trials on humans after success on monkeys

A mass roll-out of a COVID-19 vaccine in the United Kingdom could be completed in less than 3 months, with everyone possibly getting a vaccination around Easter period. This is according to a media report which cited some government scientists.

Scientists working on the Oxford vaccine are anticipating that regulators would approve it before the beginning of 2021.

Government sources say the belief is that once the process is underway, it could take 6 months to distribute the vaccine, however, the timeline could be even quicker than that.

A full COVID-19 immunization programme, which would exclude children, could be quicker than experts predicted, and health officials estimate that every adult could receive a dose of the vaccine within 6 months.

The European Medicines Agency (EMA) said on Thursday it had started reviewing data on AstraZeneca and Oxford University’s potential COVID-19 vaccine, in real-time, the first of such moves aimed at speeding up any approval process in the region for a vaccine.

GTBank 728 x 90

The news of the European review also raises chances of the British vaccine, which is seen as leading the race for a successful vaccine against COVID-19, becoming the first to be approved in Europe for the disease caused by the novel coronavirus which has killed over 1 million people globally.

The media report also added that plans under consideration by the government include allowing a much wider group of healthcare staff to administer the vaccine, setting up of drive-through vaccination centres and getting the help of armed forces.

Also, drive-through vaccination centres are being planned to cope with the huge logistical challenge of giving vaccines to tens of millions of people.

GTBank 728 x 90

Chike Olisah is a graduate of accountancy with over 15 years working experience in the financial service sector. He has worked in research and marketing departments of three top commercial banks. Chike is a senior member of the Nairametrics Editorial Team. You may contact him via his email- [email protected]

1 Comment

1 Comment

  1. Pingback: UK to roll out COVID-19 vaccine in less than 3 months and mass vaccination by Easter - Nairametrics - Coolum Online News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Coronavirus

COVID-19 Update in Nigeria

On the 25th of October 2020, 62 new confirmed cases and 1 death was recorded in Nigeria

Published

on

The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 61,992 confirmed cases.

On the 25th of October 2020, 62 new confirmed cases and 1 death was recorded in Nigeria, having carried out a total daily test of 3,824 samples across the country.

To date, 61,992 cases have been confirmed, 57,465 cases have been discharged and 1,130 deaths have been recorded in 36 states and the Federal Capital Territory. A total of 607,435 tests have been carried out as of October 25th, 2020 compared to 603,611 tests a day earlier.

COVID-19 Case Updates- 25th October 2020,

  • Total Number of Cases – 61,992
  • Total Number Discharged – 57,465
  • Total Deaths – 1,1130
  • Total Tests Carried out – 607,435

According to the NCDC, the 62 new cases were reported from 11 states- Taraba (18), Ogun (15), FCT (6), Kaduna (6), Katsina (4), Ondo (4), Ekiti (3), Rivers (3), Kano (1), Osun (1), Sokoto (1)

Meanwhile, the latest numbers bring Lagos state total confirmed cases to 20,807, followed by Abuja (5,967), Plateau (3,594), Oyo (3,423), Rivers (2,773), Edo (2,648), Kaduna (2,617), Ogun (2,010), Delta (1,812), Kano (1,742), Ondo (1,666), Enugu (1,314),  Kwara (1,067), Ebonyi (1,049), Katsina (952), Osun (923), Abia (898), Gombe (883).  Borno (745), and Bauchi (710).

GTBank 728 x 90

Imo State has recorded 614 cases, Benue (486), Nasarawa (478), Bayelsa (403),  Ekiti (332), Jigawa (325), Akwa Ibom (295), Anambra (277), Niger (274), Adamawa (257), Sokoto (165), Taraba (140), Kebbi (93), Cross River (87), Yobe (82), Zamfara (79), while Kogi state has recorded 5 cases only.

READ ALSO: COVID-19: Western diplomats warn of disease explosion, poor handling by government

Lock Down and Curfew

In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.

GTBank 728 x 90

The movement restriction, which was extended by another two-weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.

On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.

On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.

READ ALSO: Bill Gates says Trump’s WHO funding suspension is dangerous

Jaiz bank ads

 

Fidelity ads

 

 

 

 

 

Coronation ads
Continue Reading

Coronavirus

COVID-19: WHO warns against Gilead’s remdesivir drug approved by US FDA

WHO has expressed concern over the health implication of Gilead Science Inc’s recently approved remdesivir vaccine.

Published

on

remdesivir as first vaccine , Developing countries will pay less for COVID-19 drug – Gilead reveals 

The World Health Organization (WHO) has warned health officials reviewing Gilead Science Inc’s GILD.O remdesivir against COVID-19 to consider all evidence, including a trial where the medicine failed, before giving its approval to the anti-viral drug.

While making the disclosure during a news conference, Chief Scientist at WHO, Soumya Swaminathan, said that the US regulators, the Food and Drug Administration (FDA), appeared not to have considered the evidence when approving the drug this week.

Backstory

Nairametrics earlier reported that the US Food and Drug Administration on Thursday, granted full approval to Gilead’s antiviral drug for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

The approval came days after a WHO study had discovered the remdesivir anti-viral drug had little or no effect on COVID-19 patients’ length of stay in the hospital or chances of survival. WHO said it failed to prevent deaths among patients.

Swaminathan said that the FDA did not appear to have taken the global health body’s study into account in its approval.

GTBank 728 x 90

When asked about the FDA move during the news conference, Swaminathan said, “We believe our results are very robust. We hope that people who are doing treatment guidelines in other countries, as well as regulators around the world, will take note of our study results, in addition to the other evidence.”

“Because you need to look at the global evidence for a drug before you make decisions,” she added.

For the remdesivir arm of the WHO’s Solidarity trial, 2,743 patients were given the treatment, compared to 2,708 in the control group.

GTBank 728 x 90

Gilead’s own study of 1,062 participants, produced data indicating that the treatment cut COVID-19 recovery time by 5 days and helped reduce the risk of death in some patients who were getting oxygen.

The WHO said that the company, which has raised the possibility of bias in the unblinded WHO study because patients and their doctors were aware of which treatments were being used, got initial data showing that remdesivir failed the Solidarity trial in late September. However, the U.S. company said that it had told the FDA about initial Solidarity results.

The FDA did not immediately comment on Swaminathan’s statement that the U.S. agency did not take Solidarity data into account in its approval.

The WHO also disclosed on Friday that its formal guidelines on the use of remdesivir for COVID-19 should be ready for release in 3 to 4 weeks after a separate group within the United Nations health agency would have reviewed data from the study.

Jaiz bank ads
Continue Reading

Coronavirus

Covid-19: US FDA grants full approval to remdesivir as first vaccine to treat coronavirus

Remdesivir has become the first drug to obtain formal clearance for treating the coronavirus disease.

Published

on

remdesivir as first vaccine , Developing countries will pay less for COVID-19 drug – Gilead reveals 

The US Food and Drug Administration (FDA) on Thursday granted full approval to Gilead Sciences Inc. for its antiviral drug, remdesivir, making it the first drug to obtain formal clearance for treating the coronavirus disease after conditional authorization was given in May.

The regulators had granted an emergency use authorization for remdesivir earlier this year, and since then, the drug has become a widely used therapy for hospitalized Covid-19 patients. It was also reportedly given to President Donald Trump this month, when he was diagnosed with the coronavirus disease.

READ: UK to roll out COVID-19 vaccine in less than 3 months and mass vaccination by Easter

This was disclosed in a statement by Gilead Sciences on Thursday.

In its statement, Gilead said, “Veklury is now the first and only approved Covid-19 treatment in the United States.’’ While the drug was in short supply initially, Gilead said that the medicine is now widely available in hospitals across the country as manufacturing capacity has rapidly expanded.

GTBank 728 x 90

READ: COVID-19: US to have enough vaccines for vulnerable Americans by end of 2020

This is coming some days after the World Health Organization (WHO) study had discovered that the remdesivir anti-viral drug had little or no effect on Covid-19 patients’ length of stay in the hospital or chances of survival. The WHO said it failed to prevent deaths among patients.

However, Gilead has criticized the WHO study. In a letter posted on the company’s website, Chief Medical Officer Merdad Parsey said the findings didn’t negate other results.

GTBank 728 x 90

READ: Remdesivir has received FDA’s emergency approval to treat COVID-19, according to Trump

The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help solidify its position as a go-to medicine for Covid-19 patients, even as other drugs for the disease begin to reach the market.

Other treatments have received authorization for emergency use, although that approval can be revoked once the public health emergency caused by the coronavirus pandemic is over. Other medications like the steroid dexamethasone are also being used in the fight against Covid-19.

READ: COVID-19: World Bank approves $114 million response funds for Nigeria

Shares of Gilead gained 4.1% in trading after the close of regular market hours on Thursday. According to 13 analysts surveyed by Bloomberg, it is estimated that remdesivir will have sales of $2.17 billion this year.

Jaiz bank ads

The company said in June that it would charge U.S. hospitals roughly $3,120 for most patients who need remdesivir.

Fidelity ads

The approval is based on a U.S. government-sponsored trial involving over 1,000 hospitalized coronavirus patients that found that those who received the drug recovered about five days faster than those who got a placebo.

READ: Pfizer targets use of its Covid-19 vaccine by late November this year

The overall side-effect rate was similar to the placebo in the government study. The most common side effects are nausea and elevated liver enzymes, according to the product’s label.

What this means: This will be a very huge boost to the global search for a vaccine for the coronavirus pandemic which has negatively impacted on the global economy with over 1 million deaths. This also appears to be a boost for Donald Trump, who had sought the development of a Covid-19 vaccine before the US Presidential election.

Continue Reading
Advertisement
Advertisement
Advertisement
ikeja electric
Advertisement
Advertisement
Patricia
Advertisement
FCMB ads
Advertisement
IZIKJON
Advertisement
Fidelity ads
Advertisement
first bank
Advertisement
bitad
Advertisement
Stallion ads
Advertisement
financial calculator
Advertisement
deals book
Advertisement
app
Advertisement